Q-omics provides the consensus-scored YRDCP2 profile across patient tissues and cancer cell-line models. YRDCP2 expression is associated with patient survival in 9 of 34 cancer types, with the highest sampling consensus in UCS. Among the 18 cancer types available for tumor–normal comparison, YRDCP2 is differentially expressed in 1, with the highest sampling consensus in STAD. Additionally, YRDCP2 RNA expression shows 7,729 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight UCS, STAD, and GBM as cancer lineages where YRDCP2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for YRDCP2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes YRDCP2 survival associations across molecular data types. YRDCP2 RNA expression shows survival associations in the most cancer types (9). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible YRDCP2 RNA expression–survival associations across cancer types. High YRDCP2 expression shows unfavorable associations in UCS, COAD, SKCM and LIHC, but favorable associations in ACC and READ. The UCS Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UCS as the clearest survival context for YRDCP2 RNA expression.
This table summarizes YRDCP2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 1. The strongest signals are observed in STAD for RNA.
This table ranks reproducible tumor–normal expression differences for YRDCP2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. YRDCP2 shows higher tumor expression in STAD. The STAD box plot shows higher YRDCP2 RNA expression in tumor versus normal tissue (log2 FC = +0.296, t-test p < 0.001).
This table shows molecular features associated with YRDCP2 in patient tissues and cancer cell lines. In patient samples, YRDCP2 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set.
